Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
1. (r)-2-(7-((4-cyclo-pentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydro-cyclopenta(b)indol-3-yl)acetic Acid)
1. 1206123-37-6
2. Apd334
3. Apd-334
4. Etrasimod [usan]
5. 6wh8495mmh
6. Apd-334(free Acid)
7. Chembl3358920
8. Etrasimod (usan)
9. 1206123-37-6 (free Base)
10. (r)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
11. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl) Acetic Acid
12. 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic Acid
13. Etrasimod(apd334)
14. Etrasimod [inn]
15. Etrasimod [who-dd]
16. Unii-6wh8495mmh
17. Apd334apd334
18. Gtpl9331
19. Schembl1919311
20. Bcp19558
21. Ex-a1633
22. Bdbm50041691
23. Akos032944972
24. Zinc117522788
25. Apd334-003
26. Compound 4 [pmid: 25516790]
27. Cs-6181
28. Db14766
29. Ac-35444
30. Hy-12789
31. D10930
32. F10118
33. Q27265630
34. ((3r)-7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid
35. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
36. Cyclopent(b)indole-3-acetic Acid, 7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydro-, (3r)-
| Molecular Weight | 457.5 g/mol |
|---|---|
| Molecular Formula | C26H26F3NO3 |
| XLogP3 | 6.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 457.18647818 g/mol |
| Monoisotopic Mass | 457.18647818 g/mol |
| Topological Polar Surface Area | 62.3 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 695 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Lead Product(s): Obefazimod,Etrasimod
Therapeutic Area: Gastroenterology Brand Name: ABX-464
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Brand Name : ABX-464
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2024
Details:
Velsipity (etrasimod) is an FDA-approved oral S1P receptor modulator, with its NDA accepted in Macau for adults with moderately to severely active ulcerative colitis.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: Velsipity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
Details : Velsipity (etrasimod) is an FDA-approved oral S1P receptor modulator, with its NDA accepted in Macau for adults with moderately to severely active ulcerative colitis.
Brand Name : Velsipity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2024
Details:
Velsipity (etrasimod) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. It is approved for the treatment of patients with moderately to severely active ulcerative colitis.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: Velsipity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Velsipity (etrasimod) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. It is approved for the treatment of patients with moderately to severely active ulcerative coliti...
Brand Name : Velsipity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2023
Details:
Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, is approved by the FDA for adults with moderately to severely active ulcerative colitis (UC).
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: Velsipity
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative...
Details : Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, is approved by the FDA for adults with moderately to severely active ulcerative colitis (UC).
Brand Name : Velsipity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Details:
APD334 (etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for the treatment of moderate-severe active ulcerative colitis.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : APD334 (etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for the treatment of moderate-severe active ul...
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Details:
Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Everest Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflamma...
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2022
Details:
APD334 (Etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Pro...
Details : APD334 (Etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2022
Details:
Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2022
Details:
Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and ...
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2022
Details:
Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Brand Name: APD334
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: $6,700.0 million Upfront Cash: $6,700.0 million
Deal Type: Acquisition March 11, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of Arena Pharmaceuticals
Details : Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulato...
Brand Name : APD334
Molecule Type : Small molecule
Upfront Cash : $6,700.0 million
March 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Finished Drug Prices
RX/OTC/DISCN :
Dosage Form : Tablet, film-coated
Dosage Strength : 2 mg
Price Per Pack (Euro) : 1,001.09
Published in :
Country : Norway
RX/OTC/DISCN :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
31 Jul 2024
Reply
21 Dec 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Comment (7)
